share_log

Biotricity Launches Cardiac Monitoring Pilot Program With Major Hospital Network

Biotricity Launches Cardiac Monitoring Pilot Program With Major Hospital Network

Biotricity與主要醫院網絡啓動心臟監測試點計劃
Accesswire ·  04/16 19:00

REDWOOD CITY, CA / ACCESSWIRE / April 16, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, launched a pilot program with a major hospital network, encompassing over 50 hospitals across multiple states. The pilot program will demonstrate the value of Biotricity's cardiac monitoring solutions, setting the stage for a potential large-scale commercial rollout across the network.

加利福尼亞州雷德伍德城/ACCESSWIRE/2024年4月16日/Biotricity Inc.(納斯達克股票代碼:BTCY)(“Biotricity” 或 “公司”)是一家徹底改變醫療診斷和消費者醫療保健領域的領先技術即服務(TaaS)公司,啓動了一項涉及大型醫院網絡的試點計劃,涵蓋多個州的50多家醫院。該試點計劃將展示Biotricity心臟監測解決方案的價值,爲可能在整個網絡上進行大規模商業推廣奠定基礎。

"Our partnerships with leading Group Purchasing Organizations (GPOs) have rapidly enhanced our visibility and market reach, and this latest pilot program is a direct result of that improved access," said Dr. Waqaas Al-Siddiq, Biotricity founder and CEO. "We now have access to nine out of 10 hospitals through our GPO partners, placing us in an extremely strong position to secure additional pilot programs with other major hospital networks.Ultimately, our advanced hardware and proprietary software solutions are highly scalable. Successful pilots like this are crucial as they demonstrate the real-world impact and scalability of our solutions, setting the stage for widespread adoption across the healthcare landscape. Combined with our expanded reach, this not only strengthens our market position, it significantly accelerates our path to profitability."

Biotricity創始人兼首席執行官Waqaas Al-Siddiq博士表示:“我們與領先的集團採購組織(GPO)的合作伙伴關係迅速提高了我們的知名度和市場影響力,而這項最新的試點計劃是渠道改善的直接結果。”“現在,通過我們的GPO合作伙伴,我們可以訪問十分之九的醫院,這使我們在確保與其他主要醫院網絡進行更多試點計劃方面處於非常有利的地位。最終,我們的高級硬件和專有軟件解決方案具有高度的可擴展性。像這樣的成功試點至關重要,因爲它們展示了我們解決方案在現實世界中的影響力和可擴展性,爲整個醫療領域的廣泛採用奠定了基礎。再加上我們擴大了業務範圍,這不僅鞏固了我們的市場地位,還大大加快了我們的盈利之路。”

As part of the pilot program, Biotricity will collaborate closely with the hospital network to gather data, refine patient interaction protocols, and enhance the overall utility of its technology suite. This initiative is expected to provide valuable insights that will further drive the evolution of Biotricity's solutions suite to deliver award-winning, best-in-class predictive monitoring tools that pave the way for groundbreaking disease profiling, enhanced patient management, and a transformative approach to disease prevention.

作爲試點計劃的一部分,Biotricity將與醫院網絡密切合作,收集數據,完善患者互動協議,並增強其技術套件的整體實用性。該計劃預計將提供寶貴的見解,進一步推動Biotricity解決方案套件的發展,以提供屢獲殊榮的同類最佳預測監測工具,爲開創性的疾病分析、增強的患者管理和變革性的疾病預防方法鋪平道路。

Biotricity's technology-as-a-service model ensures that state-of-the-art tools are accessible without the prohibitive costs typically associated with advanced medical technologies. Biotricity's suite of innovative remote diagnostic and patient monitoring solutions address a $35 billion market opportunity.

Biotricity的 “技術即服務” 模式可確保使用最先進的工具,而不會產生通常與先進醫療技術相關的高昂成本。Biotricity的一套創新的遠程診斷和患者監護解決方案解決了350億美元的市場機會。

About Biotricity

關於 Biotricity

Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit and follow us on Twitter and LinkedIn.

Biotricity以心臟病學爲重點,彌合了遠程監測和慢性護理管理方面的差距,從而改變了醫療保健市場。醫生和患者信任 Biotricity 無與倫比的預防和個人護理標準,包括慢性病的診斷和診斷後解決方案。該公司爲醫療和消費市場開發全面的遠程健康監測解決方案。要了解更多信息,請在推特和領英上訪問並關注我們。

Important Cautions Regarding Forward-Looking Statements

關於前瞻性陳述的重要注意事項

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events, or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to several risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

本新聞稿中包含的任何未描述歷史事實的陳述均可能構成前瞻性陳述。前瞻性陳述涉及假設並描述我們未來的計劃、戰略和預期,通常可通過使用 “可能”、“應該”、“將”、“可以”、“計劃”、“預期”、“預期”、“估計”、“相信”、“打算”、“尋求”、“項目” 或 “目標” 等詞語的否定詞或這些詞語的其他變體來識別可比的術語。前瞻性陳述可能包括但不限於關於 (i) 管理層未來運營的計劃、目標和目標的陳述,包括與Bioflux或公司任何其他擬議產品或服務的設計、開發和商業化相關的計劃、目標或目標,(ii) 收入(包括收益/損失)、每股收益(包括收益/虧損)、資本支出、股息、資本結構或其他財務項目的預測,(iii)) 公司的未來財務業績,(iv) 監管公司運營或打算運營的制度,以及 (v) 上述第 (i)、(ii)、(iii) 或 (iv) 點所述任何陳述所依據或與之相關的假設。此類前瞻性陳述並不旨在預測或保證實際業績、業績、事件或情況,可能無法實現,因爲它們基於公司當前的預測、計劃、目標、信念、預期、估計和假設,並受到多種風險和不確定性以及其他影響,其中許多是公司無法控制的。由於這些風險和不確定性,實際結果以及某些事件和情況的時間可能與前瞻性陳述中所描述的存在重大差異。可能影響或助長前瞻性陳述不準確或導致實際業績與預期或預期結果存在重大差異的因素可能包括但不限於公司無法獲得額外融資、與產品開發相關的大量時間和資源以及相關的現金流不足和由此產生的流動性不足、公司無法擴大公司業務、政府對醫療器械和醫療保健行業的嚴格監管、缺乏產品多元化、現有或日益激烈的競爭、仲裁和訴訟的結果、股票波動和流動性不足,以及公司未能實施公司的業務計劃或戰略。公司向美國證券交易委員會提交的文件中更詳細地確定和描述了這些因素和其他因素。無法保證公司會盈利。公司沒有義務更新任何前瞻性陳述以反映本新聞稿發佈之日之後可能發生的任何事件或情況。

Investor Relations Contacts

投資者關係聯繫人

investors@biotricity.com

investors@biotricity.com

Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BTCY@redchip.com

戴夫·金特里
RedChip 公司有限公司
1-407-644-4256
BTCY@redchip.com

SOURCE: Biotricity, Inc.

來源:Biotricity, Inc.


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論